CaMKIIα hub ligands are unable to reverse known phenotypes in Angelman syndrome mice
Basic & Clinical Pharmacology & Toxicology · 2025
DOI: 10.1111/bcpt.14112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Stine J Gauger und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Angelman Syndrome, Calcium-Calmodulin-Dependent Protein Kinase Type 2, Phenotype, Disease Models, Animal. Die Arbeit nennt 61 Literaturangaben. Gefördert von: Novo Nordisk Foundation, Lundbeck Foundation, Novo Nordisk Fonden.
Abstract (Originalsprache)
Angelman Syndrome (AS) is a neurodevelopmental disorder caused by the loss of function of ubiquitin‐protein ligase E3A (UBE3A), resulting in marked changes in synaptic plasticity. In AS mice, a dysregulation of Ca 2+ /calmodulin‐dependent protein kinase II alpha (CaMKIIα) was previously described. This has been convincingly validated through genetic rescue of prominent phenotypes in mouse cross‐breeding experiments. Selective ligands that specifically stabilize the CaMKIIα central association (hub) domain and affect different conformational states in vitro are now available. Two of these ligands, 3‐hydroxycyclopent‐1‐enecarboxylic acid (HOCPCA) and ( E )‐2‐(5‐hydroxy‐2‐phenyl‐5,7,8,9‐tetrahydro‐6 H ‐benzo[7]annulen‐6‐ylidene)acetic acid (Ph‐HTBA), confer neuroprotection after ischemic stroke in mice where CaMKIIα is known to be dysregulated. Here, we sought to investigate whether pharmacological modulation with these prototypical CaMKIIα hub ligands presents a viable approach to alleviate AS symptoms. We performed an in vivo functional evaluation of AS mice treated for a total of 14 days with either HOCPCA or Ph‐HTBA (7 days pre‐treatment and 7 days of behavioural assessment). Both compounds were well‐tolerated but unable to revert robust phenotypes of motor performance, anxiety, repetitive behaviour or seizures in AS mice. Biochemical experiments subsequently assessed CaMKIIα autophosphorylation in AS mouse brain tissue. Taken together our results indicate that pharmacological modulation of CaMKIIα via the selective hub ligands used here is not a viable treatment strategy in AS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Genetics, Center of Expertise for Neurodevelopment (ENCORE), Rotterdam, The Netherlands.
- Institute of Organic Chemistry and Biochemistry, The Czech Academy of Sciences, Prague 6, Czech Republic.
- Department of Neuroscience, Center of Expertise for Neurodevelopment (ENCORE), Rotterdam, The Netherlands.
- Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Stine J Gauger, Maria E K Lie, Ilse Wallaard, Yongsong Tian, Aleš Marek, Bente Frølund, Geeske M van Woerden, Ype Elgersma, Birgitte R Kornum, Petrine Wellendorph
Förderung
- Novo Nordisk Foundation
- Lundbeck Foundation
- Novo Nordisk Fonden
- Lundbeckfonden
Zitieren
APA
Gauger, S. J., Lie, M. E. K., Wallaard, I., Tian, Y., Marek, A., Frølund, B., van Woerden, G. M., Elgersma, Y., Kornum, B. R., & Wellendorph, P. (2025). CaMKIIα hub ligands are unable to reverse known phenotypes in Angelman syndrome mice. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.14112
Vancouver
Gauger SJ, Lie MEK, Wallaard I, Tian Y, Marek A, Frølund B, et al. CaMKIIα hub ligands are unable to reverse known phenotypes in Angelman syndrome mice. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.14112
BibTeX
@article{Gauger2025,
author = {Gauger, Stine J and Lie, Maria E K and Wallaard, Ilse and Tian, Yongsong and Marek, Aleš and Frølund, Bente and van Woerden, Geeske M and Elgersma, Ype and Kornum, Birgitte R and Wellendorph, Petrine},
title = {CaMKIIα hub ligands are unable to reverse known phenotypes in Angelman syndrome mice},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
doi = {10.1111/bcpt.14112}
}
EUVIMED